サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：管腔形成術治療の世界市場-2023年～2030年
市場調査レポート
商品コード
1374785

管腔形成術治療の世界市場-2023年～2030年

Global Canaloplasty Treatment Market -2023-2030

出版日
ページ情報
英文 187 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
管腔形成術治療の世界市場-2023年～2030年
出版日: 2023年11月01日
発行: DataM Intelligence
ページ情報: 英文 187 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

緑内障は、眼圧の上昇を特徴とする眼疾患であり、視神経を損傷して視力低下を引き起こす可能性があります。管形成術の主な目的は、緑内障における視神経損傷と進行性視力低下の主な危険因子である眼圧上昇を低下させることです。眼球の自然な排水システムの詰まりを取り除き、広げることで、眼圧を効果的に下げ、視力を維持することができます。

緑内障の眼圧下降を長期的に持続させることで、更なる手術を回避したり、遅らせたりすることができ、頻繁な薬物治療の必要性を減らすことができます。軽度から中等度の開放隅角緑内障の方で、薬物治療で効果が得られず、手術の選択肢を探している方など、様々な方にとって、管形成術は効果的な治療法かもしれません。より侵襲的な手術に伴う危険を軽減したい患者は、さらにそれを選ぶことができます。

市場力学：市場促進要因と市場抑制要因

企業が採用する戦略

例えば、2022年4月、Nova Eye Medical Limitedは、次世代カナルプラスティ装置であるiTrack Advanceを欧州とアジアの一部の地域で提供しています。iTrack Advanceの発売は、管腔形成術分野の拡大に対する当社の献身を示すものです。同社は、iTrack Advanceの発売により、白内障外科医や一般眼科医が管形成術を行う数が増加すると予想しています。

世界のカナルプラスティ市場の売上成長を促進する主な要因の1つは、緑内障患者の増加です。緑内障の患者数は周期的に増加しており、これは緑内障が痛みを伴わない目の病気であり、かなりの視力低下が起こるまで症状が出ないためです。したがって、上記の要因が市場の成長を後押ししています。

市場力学：抑制要因

眼管形成術には多くのプラスの効果があるが、広く使用されることを妨げたり、特定の状況での適用を制限したりするものもあります。例えば、管形成術は繊細な治療法であり、外科医には高い能力と経験が要求されます。

すべての眼科医がこの手技を使いこなせるわけではなく、他の多くの高度な外科治療と同様、費用がかかるという事実によって、患者さんへの視神経管形成術の利用が制限されることがあります。特に、ヘルスケアが十分に行き届いていない地域や国、あるいは患者が医療手術の費用を自己負担しなければならないような地域では、費用が決定的な影響を及ぼす要因になる可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 緑内障疾患の増加
      • 企業が採用する戦略
  • 抑制要因
      • 治療に伴う高コスト
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • DMI意見

第6章 COVID-19分析

第7章 タイプ別

  • 従来の管腔形成術
  • マイクロカテーテル支援による管形成術

第8章 手術手技別

  • アブインターノ管形成術
  • 外耳道形成術

第9章 エンドユーザー別

  • 眼科クリニック
  • 病院
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Nova Eye Medical Limited
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Ellex Medical Lasers
  • Haag-Streit
  • New World Medical
  • Sight Sciences
  • Glaukos Corporation
  • Ophthalmic Instruments Pte Ltd.
  • New World Medical, Inc
  • Ohio Eye Alliance
  • iScience Interventional

第13章 付録

目次
Product Code: MD7193

Overview

Canaloplasty is a surgical procedure used to treat glaucoma, a group of eye conditions characterized by increased intraocular pressure (IOP) that can damage the optic nerve and lead to vision loss. The primary goal of canaloplasty is to lower elevated IOP, which is a major risk factor for optic nerve damage and progressive vision loss in glaucoma. By unblocking and widening the eye's natural drainage system, canaloplasty can effectively reduce IOP and help preserve vision.

Long-lasting IOP reduction from canaloplasty can help patients avoid or delay further procedures and lessen the need for frequent medication modifications. For a variety of individuals, including those with mild to moderate open-angle glaucoma who have not found relief from medication and are searching for a surgical option, canaloplasty may be an effective course of treatment. Patients who want to reduce the dangers connected with more invasive surgeries can additionally opt for it.

Market Dynamics: Drivers and Restraints

The strategies adopted by the companies

The strategies like product launches and technological developments of the products by the companies which accelerates the market growth.For instance, in April 2022, Nova Eye Medical Limited is offering the iTrack Advance, a next-generation canaloplasty device, in a few European and Asian regions. The launch of the iTrack Advance demonstrates our dedication to expanding the canaloplasty sector. The company anticipates that the release of iTrack Advance will lead to an increase in the number of cataract surgeons and general ophthalmologists performing canaloplasty procedures.

One of the main factors propelling the growth of the worldwide canaloplasty market's revenue is the rise in glaucoma cases. The number of glaucoma patients is cyclically increasing because the condition is a painless eye ailment that does not cause symptoms until there is considerable vision loss. Thus above factors boost the market growth.

Market Dynamics: Restraint

Canaloplasty has a number of positive effects but there are also certain things that can prevent it from being widely used or limit its application in specific circumstances. For instance, canaloplasty is a sensitive treatment that demands a surgeon to have a high level of competence and experience.

The availability of canaloplasty to patients may be constrained by the fact that not all eye surgeons are skilled in using this technique, and it can be costly, like many other sophisticated surgical treatments. Particularly in areas or nations with inadequate healthcare coverage or where patients must pay out-of-pocket for medical operations, the cost may be a crucial influencing factor.

Segment Analysis

The global canaloplasty treatment market is segmented based on type, surgical techniques, end-user and region.

The microcatheter-assisted canaloplasty segment from the type segment accounted for approximately 41.7% of canaloplasty treatment share

Microcatheter-assisted canaloplasty is a minimally invasive procedure. It avoids the need for major incisions and reduces trauma to the eye. This minimizes post-operative discomfort and promotes faster recovery compared to traditional, more invasive glaucoma surgeries. Ongoing advancements in microcatheter technology and surgical techniques continue to refine and improve the outcomes of microcatheter-assisted canaloplasty, making it an increasingly viable option for glaucoma patients.

Additionally, the novel products helps to accelerates the segment growth. For instance, in March 2021, Sight Sciences, Inc., a growth-stage Medical Device company focused on addressing the underlying causes of the world's most common eye conditions, the OMNI Surgical System (OMNI) had approved USFDA 510(k) clearance for canaloplasty (microcatheterization and transluminal vasodilation of Schlemm's canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce Intraocular Pressure (IOP). Thus above factors boost the segment growth.

Geographical Analysis

North America Accounted for Approximately 38.4% of the Market Share in 2022

North America is expected to account for the largest revenue share over the forecast period. Leading market players' presence, efficient reimbursement policies, and public health programs such as Eye America and rise of glaucoma helps to boost the region growth. For instance, according to CDC, a series of illnesses known as glaucoma harm the optic nerve in the eye, which can lead to vision loss and even blindness.

Glaucoma affects about 3 million Americans. It is the second most common cause of blindness in the globe. The most prevalent type of glaucoma, open-angle glaucoma, causes an increase in ocular pressure. Since glaucoma frequently has no early symptoms, 50% of those who have it are unaware that exist. Due to improvements in healthcare infrastructure, rising disposable income, the established presence of domestic companies in the region, the availability of glaucoma surgery devices, healthcare reforms, and technological advancements, Asia Pacific is predicted to experience significant revenue over the forecast period.

COVID-19 Impact Analysis

Restrictions and safety concerns initially limited patient access to treatment centers. Yet, as restrictions relaxed, there was a noticeable market recovery, emphasizing minimally invasive procedures and a rise in telemedicine consultations. Manufacturers and healthcare providers adjusted to the new circumstances by enforcing rigorous safety measures. The market's progress is steadily improving as healthcare systems stabilize and patient confidence rebounds. Future growth is fueled by innovation and a patient-focused approach.

Competitive Landscape

The major global players in the market include: Nova Eye Medical Limited, Ellex Medical Lasers, Haag-Streit, New World Medical, Sight Sciences, Glaukos Corporation, Ophthalmic Instruments Pte Ltd., New World Medical, Inc, Ohio Eye Alliance, iScience Interventional and among others.

Key Developments

  • In November 10, 2021, the Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE) authorising the company to conduct a clinical study to evaluate the safety and effectiveness of a new, higher volume, investigational OMNI device ("higher volume OMNI") to perform canal viscodilation alone to lower intraocular pressure. Sight Sciences, Inc. is an eyecare technology company focused on developing innovative solutions intended to transform standards of care and improve patients' lives.

Why Purchase the Report?

  • To visualize the global canaloplasty treatment market segmentation based on type, surgical techniques, end-user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of canaloplasty treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global canaloplasty treatment market report would provide approximately 61 tables, 63 figures and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Surgical Techniques
  • 3.3. Snippet by End-user
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rise of glaucoma diseases
      • 4.1.1.2. The strategies adopted by the companies
  • 4.2. Restraints
      • 4.2.1.1. High cost associated with the treatment
    • 4.2.2. Opportunity
    • 4.2.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Traditional Canaloplasty *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Microcatheter-assisted Canaloplasty

8. By Surgical Techniques

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgical Techniques
    • 8.1.2. Market Attractiveness Index, By Surgical Techniques
  • 8.2. Ab-interno canaloplasty *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Ab-externo canaloplasty

9. By End-user

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 9.1.2. Market Attractiveness Index, By End-user
  • 9.2. Ophthalmology clinics *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Hospitals
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgical Techniques
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgical Techniques
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgical Techniques
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgical Techniques
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgical Techniques
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Nova Eye Medical Limited *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Ellex Medical Lasers
  • 12.3. Haag-Streit
  • 12.4. New World Medical
  • 12.5. Sight Sciences
  • 12.6. Glaukos Corporation
  • 12.7. Ophthalmic Instruments Pte Ltd.
  • 12.8. New World Medical, Inc
  • 12.9. Ohio Eye Alliance
  • 12.10. iScience Interventional

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us